Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces Warrant Exercise
Ablynx NV (Ablynx) announced that an additional 61,812 common shares have been issued by the Company in exchange for EUR 329,619.51 as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx has 43,779,197 shares outstanding.
Latest Developments for Ablynx NV
- Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
- Ablynx NV Elects New Chairman Of Board
- Ablynx NV Updates on Phase II Part of Combined Phase I/II Study of Anti-IL-6R Nanobody, ALX-0061 Results
- Ablynx NV Updates on Results of Phase I/II Study with Anti-Il-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces board authorization of up to $2 million stock repurchase program
- Insys Therapeutics Inc receives subpoena from Office of Inspector General
- Synta Pharmaceuticals Corp announces positive interim results from the ENCHANT-1 Trial
- Celator Pharmaceuticals Inc announces positive data and safety monitoring board recommendation for CPX-351 Phase 3 Study
- Share this
- Digg this